Tumor suppressor genes in myeloid differentiation and leukemogenesis

Future Oncology

Volumn 5, Issue 2, 2009, Pages 245-257

  Britschgi, Christian ^a   Fey, Martin F ^a,b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

Acute myeloid leukemia; ARF; Chronic myeloid leukemia; INK4a; P53; PML; Tumor suppressor gene

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTILEUKEMIC AGENT; ARSENIC TRIOXIDE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYTARABINE; CYTOTOXIC AGENT; HISTONE DEACETYLASE INHIBITOR; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN MDM2; PROTEIN P53; RETINOIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; BONE MARROW CELL; CANCER SURVIVAL; CELL ACTIVITY; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CELL PROLIFERATION; CHROMOSOME ABERRATION; CHRONIC MYELOID LEUKEMIA; DISEASE COURSE; DNA DAMAGE; DNA REPLICATION; DRUG TARGETING; GENE ACTIVATION; GENE DISRUPTION; GENE INACTIVATION; GENE MUTATION; HEMATOPOIESIS; HUMAN; LEUKEMIA; LEUKEMIA REMISSION; LEUKEMOGENESIS; MALIGNANT TRANSFORMATION; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; REVIEW; TUMOR SUPPRESSOR GENE; CELL TRANSFORMATION; CYTOLOGY; GENETICS; HEMATOPOIETIC STEM CELL; MYELOID LEUKEMIA; PHYSIOLOGY;

CELL DIFFERENTIATION; CELL TRANSFORMATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA, MYELOID;

EID: 66349102835     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.5.2.245     Document Type: Review

References (82)

1. Levine AJ, Hu W, Feng Z: Tumor suppressor genes. In: The Molecular Basis of Cancer. Mendelsohn J, Howley PM, Israel MA, Liotta LA (Eds). Saunders Elsevier, PA, USA, 31-38 (2008).
2. Knudson AG: Two genetic hits (more or less) to cancer. Nat. Rev. Cancer 1, 157-162 (2001).
3. Friend SH, Bernards R, Rogeli S et al.: A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 323, 643-646 (1986).
4. Inoue K, Mallakin A, Frazier DP: Dmp1 and tumor suppression. Oncogene 26, 4329-4335 (2007).
5. Jones PA, Baylin SB: The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 3, 415-428 (2002).
6. Laiosa CV, Stadtfeld M, Graf T: Determinants of lymphoid-myeloid liheage diversification. Annu. Rev. Immunol. 24, 705-738 (2006).
7. Tenen DG: Disruption of differentiation in human cancer: AML shows the way. Nat. Rev. Cancer 3, 89-101 (2003).
8. Akashi K, Traver D, Miyamoto T, Weissman IL: A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. Nature 404, 193-197 (2000).
9. Rosenbauer F, Tenen DG: Transcription factors in myeloid development: balancing differentiation with transformation. Nat. Rev. Immunol. 7, 105-117 (2007).
10. Zhang DE, Zhang P, Wang ND, Hetherington CJ, Darlington GJ, Tenen DG: Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein α-deficient mice. Proc. Natl Acad. Sci. USA 94, 569-574 (1997).
11. Estey E, Dohner H: Acute myeloid leukaemia. Lancet 368, 1894-1907 (2006).
12. Pabst T, Mueller BU, Zhang P et al.: Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-α (C/ EBPα), in acute myeloid leukemia. Nat. Genet. 27, 263-270 (2001).
13. Mistry AR, Pedersen EW, Solomon E, Grimwade D: The molecular pathogenesis of acute promyelocytic leukaemia: implications for the clinical management of the disease. Blood Rev. 17, 71-97 (2003).
14. Ryningen A, Stapnes C, Paulsen K, Lassalle P, Gjertsen BT, Bruserud O: In vivo biological effects of ATRA in the treatment of AML. Expert Opin. Investig. Drugs 17, 1623-1633 (2008).
15. Soriano AO, Yang H, Faderl S et al.: Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 110, 2302-2308 (2007).
16. Frohling S, Scholl C, Gilliland DG, Levine RL: Genetics of myeloid malignancies: pathogenetic and clinical implications. J. Clin. Oncol. 23, 6285-6295 (2005).
17. Ley TJ, Mardis ER, Ding L et al.: DNA-sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 456, 66-72 (2008).
18. Toyota M, Kopecky KJ, Toyota MO, Jair KW, Willman CL, Issa JP: Methylation profiling in acute myeloid leukemia. Blood 97, 2823-2829 (2001).
19. Yang AS, Doshi KD, Choi SW et al.: DNA methylation changes after 5-aza-2′-deoxycytidine therapy in patients with leukemia. Cancer Res. 66, 5495-5503 (2006).
20. Odenike OM, Alkan S, Sher D et al.: Histone deacetylase inhibitor romidepsin has differential activity in core binding factor acute myeloid leukemia. Clin. Cancer Res. 14, 7095-7101 (2008).
21. Matas D, Milyavsky M, Shats I, Nissim L, Goldfinger N, Rotter V: p53 is a regulator of macrophage differentiation. Cell Death Differ. 11, 458-467 (2004).
22. Obad S, Brunnstrom H, Vallon-Christersson J, Borg A, Drott K, Gullberg U: Staf50 is a novel p53 target gene conferring reduced clonogenic growth of leukemic U-937 cells. Oncogene 23, 4050-4059 (2004).
23. Vogelstein B, Lane D, Levine AJ: Surfing the p53 network. Nature 408, 307-310 (2000).
24. Vousden KH, Lu X: Live or let die: the cell's response to p53. Nat. Rev. Cancer 2, 594-604 (2002).
25. Levine AJ: p53, the cellular gatekeeper for growth and division. Cell 88, 323-331 (1997).
26. Nakano K, Vousden KH: PUMA, a novel proapoptotic gene, is induced by p53. Mol. Cell 7, 683-694 (2001).
27. Britschgi C, Jenal M, Rizzi M et al.: HIC1 tumour suppressor gene is suppressed in acute myeloid leukaemia and induced during granulocytic differentiation. Br. J. Haematol. 141, 179-187 (2008).
28. Britschgi C, Rizzi M, Grob TJ et al.: Identification of the p53 family-responsive element in the promoter region of the tumor supressor gene hypermethylated in cancer 1. Oncogene 25, 2030-2039 (2006).
29. Hu G, Zhang W, Deisseroth AB: P53 gene mutations in acute myelogenous leukaemia. Br. J. Haematol. 81, 489-494 (1992).
30. Seliger B, Papadileris S, Vogel. D et al.: Analysis of the p53 and MDM-2 gene in acute myeloid leukemia. Eur. J. Haematol. 57, 230-240 (1996).
31. Wattel E, Preudhomme C, Hecquet B et al.: p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 84, 3148-3157 (1994).
32. Haferlach C, Dicker F, Herholz H, Schnittger S, Kern W, Haferlach T: Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype. Leukemia 22, 1539-1541 (2008).
33. Moll UM, Petrenko O: The MDM2-P53 interaction. Mol. Cancer Res. 1, 1001-1008 (2003).
34. Bueso-Ramos CE, Yang Y, deLeon E, McCown P, Stass SA, Albitar M: The human MDM-2 oncogene is overexpressed in leukemias. Blood 82, 2617-2693 (1993).
35. Longo L, Trecca D, Biondi A et al.: Frequency of RAS and p53 mutations in acute promyelocytic leukemias. Leuk. Lymphoma 11, 405-410 (1993).
36. de Stanchina E, Querido E, Narita M et al.: PML is a direct p53 target that modulates p53 effector functions. Mol. Cell 13, 523-535 (2004).
37. Insinga A, Monestiroli S, Ronzoni S et al.: Impairment of p53 acetylation, stability and function by in oncogenic transcription factor. Embo. J. 23, 1144-1154 (2004).
38. Knudsen ES, Knudsen KE: Tailoring to RB: tumour suppressor status and therapeutic response: Nat. Rev. Cancer 8(9), 714-724 (2008).
39. Porse BT, Pedersen TA, Xu X et al.: E2F repression by C/ EBPα is required for adipogenesis and granulopoiesis in vivo. Cell 107, 247-258 (2001).
40. Gery S, Gombart AF, Fung YK, Koeffler HP: C/EBPε interacts with retinoblastoma and E2F1 during granulopoiesis. Blood 103, 828-835 (2004).
41. Krug U, Ganser A, Koeffler HP: Tumor suppressor genes in normal and malignant hematopoiesis. Oncogene 2l, 3475-3495 (2002).
42. Chim CS, Liang R, Tam CY, Kwong YL: Methylation of p15 and p16 genes in acute promyelocytic leukemia: potential diagnostic and prognostic significance. J. Clin. Oncol. 19, 2033-2040 (2001).
43. Schwaller J, Pabst T, Koeffler HP et al.: Expression and regulation of G1 cell-cycle inhibitors (p16INK4A, p15INK4B, p18INK4C, p19INK4D) in human acute myeloid leukemia and normal myeloid cells. Leukemia 11, 54-63 (1997).
44. Sherr CJ: Divorcing ARF and p53: an unsettled case. Nat. Rev. Cancer 6, 663-673 (2006).
45. Faderl S, Kantarjian HM, Estey E et al.: The prognostic significance of p16(INK4a)/p14 (ARF) locus deletion and MDM-2 protein expression in adult acute myelogenous leukemia. Cancer 89, 197-1982 (2000).
46. Grisendi S, Mecucci C, Falini B, Pandolfi PP: Nucleophosmin and cancer. Nat. Rev. Cancer 6, 493-505 (2006).
47. Falini B, Mecucci C, Tiacci E et al.: Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N. Engl. J. Med. 352, 254-266 (2005).
48. Colombo E, Martinelli P, Zamponi R et al.: Delocalization and destabilization of the Arf tumor suppressor by the leakemia-associated NPM mutant. Cancer Res. 66, 3044-3050 (2006).
49. Kurki S, Peltonen K, Latonen L et al.: Nucleolar protein NPM interacts with HDM2 and protects tumor suppressor protein p53 from HDM2-mediated degradation. Cancer Cell 5, 465-475 (2004).
50. Linggi B, Muller-Tidow C, van de Locht L et al.: The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia. Nat. Med. 8, 743-750 (2002).
51. Moreno-Mirilles I, Pan L, Keates-Baleeiro J et al.: The inv(16) cooperates with ARF haploinsufficiency to induce acute myeloid leukemia. J. Biol. Chem. 280, 40097-40103 (2005).
52. Bernardi R, Pandolfi PP: Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nat. Rev. Mol. Cell. Biol. 8, 1006-1016 (2007).
53. Fogal V, Gostissa M, Sandy P et al.: Regulation of p53 activity in nuclear bodies by a specific PML isoform. Embo. J. 19, 6185-6195 (2000).
54. Buschbeck M, Uribesalgo I, Ledl A et al.: PML4 induces differentiation by Myc destabilization. Oncogene 26, 3415-3422 (2007).
55. Yoshida H, Ichikawa H, Tagata Y et al.: PML-retinoic acid receptor α inhibits PML IV enhancement of PU.1-induced C/EBPε expression in myeloid differentiation. Mol. Cell. Biol. 27, 5819-5834 (2007).
56. Nguyen LA, Pandolfi PP, Aikawa Y, Tagata Y, Ohki M, Kitabayashi I: Physical and functional link of the leukemia-associated factors AML1 and PML. Blood 105, 291-300 (2005).
57. Lin HK, Bergmann S, Pandolfi PP: Cytoplasmic PML function in TGF-β signalling. Nature 431, 205-211 (2004).
58. Dror N, Rave-Harel N, Burchert A et al.: Interferon regulatory factor-8 is indispensable for the expression of promyelocytic leukemia and the formation of nuclear bodies in myeloid cells. J. Biol. Chem. 282, 5633-5640 (2007).
59. Bernardi R, Scaglioni PP, Bergmann S, Horn HF, Vousden KH, Pandolfi PP: PML regulates p53 stability by sequestering Mdm2 to the nucleolus. Nat. Cell Biol. 6, 665-672 (2004).
60. Yang S, Kuo C, Bisi JE, Kim MK: PML-dependent apoptosis after DNA damage is regulated by the checkpoint kinase hCdsl/Chk2. Nat. Cell Biol. 4, 865-870 (2002).
61. Lallemand-Breitenbach V, Jeanne M, Benhenda S et al.: Arsenic degrades PML or PML-RARα through a SUMO-triggered RNF4/ ubiquitin-mediated pathway. Nat. Cell Biol. 10, 547-555 (2008).
62. Tatham MH, Geoffroy MC, Shen L et al.: RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nat. Cell Biol. 10, 538-546 (2008).
63. Ito K, Bernardi R, Morotti A et al.: PML targeting eradicates quiescent leukaemia-initiating cells. Nature 453, 1072-1078 (2008).
64. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM: The biology of chronic myeloid leukemia. N. Engl. J. Med. 341, 164-172 (1999).
65. Melo JV, Barnes DJ: Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat. Rev. Cancer 7, 441-453
66. Dierov J, Dierova R, Carroll M: BCR/ABL translocates to the nucleus and disrupts an ATR-dependent intra-S phase checkpoint, Cancer Cell 5, 275-285 (2004).
67. Deutsch E, Dugray A, AbdulKarim, B et al.: BCR-ABL down-regulates the DNA repair protein DNA-PKcs. Blood 97, 2084-2090 (2001).
68. Perrotti D, Cesi V, Trotta R et al.: BCR-ABL suppresses C/ EBPα expression through inhibitory action of hnRNP E2. Nat. Genet. 30, 48-58 (2002).
69. von Lindern M, van Baal S, Wiegant J, Raap A, Hagemeijer A, Grosveld G: Can, a putative oncogene associated with myeloid leukemogenesis, may be activated by fusion of its 3′ half to different genes: characterization of the set gene. Mol. Cell. Biol. 12, 3346-3355 (1992).
70. Neviani P, Santhanam R, Trotta R et al.: The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell 8, 355-368 (2005).
71. Feinstein E, Cimino G, Gale RP et al.: p53 in chronic myelogenous leukemia in acute phase. Proc. Natl Acad. Sci. USA 88, 6293-6297 (1991).
72. Trotta R, Vignudelli T, Candini O et al.: BCR/ABL activates mdm2 mRNA translation via the La antigen. Cancer Cell 3, 145-160 (2003).
73. Hernandez-Boluda JC, Cervantes F, Colomer D et al.: Genomic p16 abnormalities in the progression of chronic myeloid leukemia into blast crisis: a sequential study in 42 patients. Exp. Hematol. 31, 204-210 (2003).
74. Martins CP, Brown-Swigart L, Evan GI: Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 127, 1323-1334 (2006).
75. XUe W, Zender L, Miething C et al.: Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445, 656-660 (2007).
76. Vassilev LT, Vu BT, Graves B et al.: In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844-848 (2004).
77. Kojima K, Konopleva M, Samudio IJ et al.: MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood 106, 3150-3159 (2005).
78. Issaeva N, Bozko P, Enge M et al.: Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat. Med. 10, 1321-1328 (2004).
79. Nahi H, Selivanova G, Lehmann S et al.: Mutated and non-mutated TP53 as targets in the treatment of leukaemia. Br. J. Haematol. 141, 445-453 (2008).
80. Bykov VJ, Issaeva N, Shilov A et al.: Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat. Med. 8, 282-288 (2002).
81. Nahi H, Merup M, Lehmann S et al.: PRIMA-1 induces apoptosis in acute myeloid leukaemia cells with p53 gene deletion. Br. J. Haematol. 132, 230-236 (2006).
82. Motzer RJ, Hutson TE, Tomczak P et al.: Sunitinib versus interferon α in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 115-124 (2007).